ENTA Research and Charts

ENTA - Enanta Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-02-24 (Delayed quote data 2025-04-04)

Last 4.73	Change ⇓ -0.32 (-6.34%)	Volume 397,313
	Open 4.87	High 5.01	Low 4.52

8EMA (Daily) 5.36	40EMA (Daily) 6.26	50EMA (Daily) 6.39	STO (Daily) 6.173	MACD Hist (Daily) -0.290
8EMA (Weekly) 6.100	40EMA (Weekly) 8.83	50EMA (Weekly) 9.83	STO (Weekly) 32.068	MACD Hist (Weekly) 0.167


Company Profile
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.